Deacetylation of Low Molecular Weight Chitosan on the Bioactivity of Oral Insulin Preparations. *Marine Drugs*, 13(4), 1710-1725.

- Rieux, A., Fievez, V., Garinot, M., Schneider, Y., & Preat, V. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. *J Control Release*, 116(1), 1-27.

- Roth, R. A. (1981). Bacitracin: an inhibitor of the insulin degrading activity of glutathione-insulin transhydrogenase. *Biochem. Biophys. Res. Commun.*, 98(2), 431-439.

- Sadeghi, A.,Dorkoosh, F., Avadi, M., Saadat, P., Rafiee-Tehrani, M., & Junginger, H. (2008). Preparation, characterization and antibacterial activities pf chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. *Int J Pharm*, 355(2), 299-306.

- Sahin, S., & Rowland, M. (2000). Evaluation of route of input on the hepatic disposition of diazepam. *JPET*, 295: 836-843.

- Sailaja, A.K., Amareshwar, P., & Chakravarty, P. (2010). Chitosan nanoparticles as a drug delivery system. RJPBCS , 1(3), 475-484.

- Sajeesh, S., & Sharma, C. (2006). Cyclodextrin–insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. *International Journal Of Pharmaceutics*, 325(1-2), 147-154.

- Sarmento, B., & das Neves, J. (2012). *Chitosan-Based Systems for Biopharmaceuticals*. New York, NY: John Wiley & Sons.

- Sarmento, B., Ribeiro, A., Veiga, F., Sampaio, P., Neufeld, R., & Ferreira, D. (2007). Alginate/Chitosan Nanoparticles are Effective for Oral Insulin Delivery. *Pharm Res*, 24(12), 2198-2206.